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Background  
In the clinical setting, biofilms were thought to be an alternative phenotype to planktonic pure cultures but scientific 
evidence from the last decade has revealed that bacteria, similar to more evolved species, undergo a specific lifecycle 
containing: (i) biofilm formation (ii) dispersion and (iii) planktonic growth phases. This results in constant alterations in 
bacterial physiology, with significant consequences to the outcome of biofilm-related infections. S. epidermidis, a common 
commensal of the human skin and mucosae, is the leading causative agent of medical device-associated infections due to 
its tenacious ability to form biofilms. Here, we performed a multi-factorial analysis to understand how the physiological 
alterations associated with S. epidermidis biofilm lifecycle enable this bacterium to (i) evade the host immune response, (ii) 
tolerate higher concentrations of antibiotics, and (iii) avoid detection by standard diagnostic methods.  
Methods 
We developed in vitro models to obtain biofilms with distinct proportions of dormant bacteria (1), as well as to collect 
biofilm dispersed cells (2). The host immune response was assessed using an in vivo murine model and characterized by 
analyzing the transcriptome of splenocytes, cytokine levels in the serum and bacterial colonization in the host. Antibiotic 
tolerance to vancomycin, rifampicin and tetracycline was assessed by CFU counting and flow cytometry. Confocal laser 
scanning microscopy was used to assess structural differences in biofilms exposed to antibiotics.  
Results & conclusions  
Mouse organs colonization and splenocytes transcriptome demonstrated that bacteria in the different stages of the 
biofilm lifecycle presented distinct and unique adaptations to the host immune response. Biofilm cells induced a lower 
production of pro-inflammatory cytokines. Conversely, the cells’ tolerance to antibiotics was higher. Presumably, this will 
allow a more efficient evasion from the host immune response and antimicrobial therapy. Furthermore, we observed that 
cells dispersed from biofilms, retained their high tolerance to antibiotics, confirming that tolerance is a phenomenon not 
only related to the tridimensional structure of biofilms. Finally, we observed that after antimicrobial treatment, significant 
discrepancies between CFU counts and the total load of viable but not cultivable bacteria, could explain the high rates of 
diagnose failure and recurrence rates.  
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